Redefining Immune Therapy: Electra Therapeutics Raises $183 Million to Battle Deadly Hyperinflammation and Cancer
In the complex world of immune-mediated diseases, where treatment options often fall short, Electra Therapeutics is carving a distinct path. The late-stage biotech, based in the U.S., has secured a robust $183 million in Series C funding to advance its groundbreaking precision therapies targeting severe immunological conditions and hematologic cancers. The financing round, co-led by…
